Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in pr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Transl Med
Main Authors: Takada, Koji, Kashiwagi, Shinichiro, Goto, Wataru, Asano, Yuka, Takahashi, Katsuyuki, Takashima, Tsutomu, Tomita, Shuhei, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883877/
https://ncbi.nlm.nih.gov/pubmed/29615076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1460-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki